Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860960 | 0.87 | NPSR1 (0.55) | KMT2ANPSR1MEN1ADORA3KDM4E | |
| SCHEMBL1856307 | 0.84 | ALDH1A1 (0.45) | KMT2ANPSR1MEN1ADORA3KDM4E | |
| SCHEMBL1853292 | 0.84 | ALDH1A1 (0.37) | KMT2ANPSR1MEN1ADORA3KDM4E | |
| SCHEMBL31564330 | 0.82 | MEN1 (0.50) | KMT2ANPSR1MEN1ADORA3KDM4E | |
| SCHEMBL31563935 | 0.75 | NPSR1 (0.43) | KMT2ANPSR1MEN1ADORA3KDM4E | |
| SCHEMBL31564438 | 0.74 | ADORA2A (0.46) | KMT2ANPSR1MEN1ADORA3KDM4E | |
| SCHEMBL1857317 | 0.74 | NPSR1 (0.65) | KMT2ANPSR1MEN1ADORA3KDM4E | |
| SCHEMBL1864398 | 0.74 | S1PR1 (0.43) | ADORA3S1PR1S1PR3ALDH1A1PKM | |
| SCHEMBL12214308 | 0.73 | S1PR1 (0.38) | S1PR1S1PR3 | |
| SCHEMBL1855921 | 0.73 | S1PR1 (0.38) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039644-B2 | Hydrogenated benzo (C) thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-8039644-B2 | Hydrogenated benzo (C) thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-8039644-B2 | Hydrogenated benzo (C) thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| EP-1863787-B1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-05-25 | — | — | EP | disclosed |
| EP-1863787-B1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-20100204198-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204198-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204198-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-08-12 | — | — | US | disclosed |
| US-7723378-B2 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-05-25 | — | — | US | disclosed |
| US-7723378-B2 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-05-25 | — | — | US | disclosed |
| US-7723378-B2 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-07-24 | — | — | US | disclosed |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-07-24 | — | — | US | disclosed |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-07-24 | — | — | US | disclosed |
| EP-1863787-A1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204198-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | NFATC1, ICOS, TPMT | KMT2A 2512/4885NPSR1 1208/4885MEN1 4419/4885 |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | S1PR1, S1PR3, S1PR5 | KMT2A 2982/4885NPSR1 463/4885MEN1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.